Deproteinized Calf Blood Extract for Pharmacological Correction of Microcirculatory Disorders in Chronic Venous Disease

Gudymovich V.G.; Stoyko Yu.M.; Fedorovich A.A.

doi:https://doi.org/10.17116/flebo202115041284

Gudymovich V.G.

Pirogov National Medical and Surgical Center

ORCID: 0000-0002-8258-1675

Stoyko Yu.M.

N.I. Pirogov National Medical and Surgical Center

SPIN RSCI: 8835-0076
Scopus AuthorID: 57217151957
ORCID: 0000-0002-3394-5858

Fedorovich A.A.

National Medical Research Center for Therapy and Preventive Medicine;
Institute of Biomedical Problems

Deproteinized Calf Blood Extract for Pharmacological Correction of Microcirculatory Disorders in Chronic Venous Disease

Authors:

Gudymovich V.G., Stoyko Yu.M., Fedorovich A.A.

More about the authors

Journal: Journal of Venous Disorders. 2021;15(4): 284‑288

DOI: 10.17116/flebo202115041284

Read: 2792 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gudymovich VG, Stoyko YuM, Fedorovich AA. Deproteinized Calf Blood Extract for Pharmacological Correction of Microcirculatory Disorders in Chronic Venous Disease. Journal of Venous Disorders. 2021;15(4):284‑288. (In Russ.)
https://doi.org/10.17116/flebo202115041284

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effect of deproteinized calf blood extract on serum concentration of some markers of endothelial dysfunction (ED) in patients with chronic venous insufficiency.

MATERIAL AND METHODS

A laboratory study of ED markers enrolled 34 patients with long-standing chronic venous disease (CVD) CEAP C4-C5 including 14 (41%) men and 20 (59%) women. Mean age of patients was 49.0±6.5 years. Duration of CVD ranged from 3 to 24 years (mean 8.9±4.3). CEAP C4 was detected in 19 (56%) patients, other 15 (44%) patients had CEAP C5. Deproteinized calf blood extract 400 mg (10 ml) was injected intravenously once a day for 10-14 days. ED markers were assessed at admission and after therapy. We analyzed sE-selectin, sP-selectin, sICAM-1 and sVCAM-1.

RESULTS

We found significant discordant change in the level of selectins (increase of sE-selectin and decrease of sP-selectin). This finding can be considered as the first stage in suppression of inflammatory response due to decrease of “fast” selectins and temporary preserving activity of E-selectins on the background of recovery of microvascular endothelial function. Tendency to decrease in inflammatory endothelium-mediated reactions is confirmed by significant decrease in the level of sICAM-1 and sVCAM-1.

CONCLUSION

Deproteinized calf blood extract injections in patients with CVD CEAP C4-C5 are followed by positive changes in serum markers of endothelial function (decrease of sP-selectin, sICAM-1 and sVCAM-1, as well as increase of sE-selectin).

Keywords:

chronic venous insufficiency

microcirculation

endothelial dysfunction

deproteinized calf blood extract

Authors:

Gudymovich V.G.

Pirogov National Medical and Surgical Center

ORCID: 0000-0002-8258-1675

Stoyko Yu.M.

N.I. Pirogov National Medical and Surgical Center

SPIN RSCI: 8835-0076
Scopus AuthorID: 57217151957
ORCID: 0000-0002-3394-5858

Fedorovich A.A.

National Medical Research Center for Therapy and Preventive Medicine;
Institute of Biomedical Problems

Received:

18.08.2021

Accepted:

30.09.2021

Close metadata

References:

Rabe E, Puskas A, Scuderi A, Fernandez Quesada F; VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105-115.
Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000;51(1):31-37. https://doi.org/10.1177/000331970005100107
Guekh A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48(5):1262-1270. https://doi.org/10.1161/STROKEAHA.116.014321
Reichl F-X, Holdt LM, TeupserD, Schütze G, Metcalfe AJ, Hicke R, Högg C, Bloch W. Comprehensive Analytics of Actovegin and Its Effect on Muscle Cells. Int J Sports Med. 2017;38(11):809-818. https://doi.org/10.1055/s-0043-115738
Buchmayer F, Pleiner J, Elminger MW, Lauer G, Nell G, Sitte H. Actovegin: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161 (3-4):80-88. https://doi.org/10.1007/s10354-011-0865-y
Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim-Forsch. 1965;15(756):757.
Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991; 146(1):148-155.
Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MG, Volpi I, Fiorentini G, Zamboni P, Secchiero P. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PloS One. 2012;7(6):1-13.
Shevchenko YuL, Stoyko YuM, Gudymovich VG. Endothelial dysfunction and damage (pathophysiology, diagnosis, clinical manifestations and treatment). M.: Lika; 2015. (In Russ.).
Shevchenko YuL, Stoyko YuM, Gudymovich VG, Chernyago TYu. Glycocalyx is a determining factor in the development of endothelial venous dysfunction and the possibility of its correction. Angiologya i sosudistaya khirurgiya. 2020;26(4):71-76. (In Russ.).
Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology. 1997;48(1):45-49.
Jünger M, Steins A, Hahn M, Häfner HM. Microcirculatory Dysfunction in Chronic Venous Insufficiency (CVI). Microcirculation. 2000;7(6 Pt 2):3-12. https://doi.org/10.1111/j.1549-8719.2000.tb00145.x
Reichl FX, Högg C, Liu F, Schwarz M, Teupser D, Hickel R, Bloch W, Schweikl H, Thomas P, Summer B. Actovegin reduces PMA-induced inflammation on human cells. European Journal of Applied Physiology. 2020; 120:1671-1680. https://doi.org/10.1007/s00421-020-04398-2
Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. International Journal of Molecular Sciences. 2018;19(6):1669.
Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvascular Research. 2012;84(1):86-93. https://doi.org/10.1016/j.mvr.2012.03.011
Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. Neuromolecular Med. 2011;13(4):266-274. https://doi.org/10.1007/s12017-011-8157-7
Astashkin EI, Glezer MG, Vinokurov MG, Egorova ND, Orekhova NS, Novikova AN, Grachev SV, Yurinskaya MN, Sobolev KE. Actovegin reduces the level of oxygen radicals in whole blood samples of patients with heart failure and suppresses the development of necrosis of human transplanted neurons of the SK-N-SH line. Doklady Akademii nauk. 2013;448(2):232-235. (In Russ.). https://doi.org/10.7868/S0869565213020278
Fedorovich AA, Soboleva GN. The state of the microcirculation system in patients with arterial hypertension in combination with coronary heart disease and cognitive impairment on Actovegin therapy. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya. 2015;3(55):40-51. (In Russ.).